Corticosteroid-sparing agents: New treatment options

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 47-56

  Tomkins Netzer, Oren ^a,b   Taylor, Simon R J ^a,b,c   Lightman, Sue ^a,b,c  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; HUMAN; TREATMENT OUTCOME; UVEITIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME; UVEITIS;

EID: 84860859578     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336186     Document Type: Article

References (91)

1. Sallam A, Taylor SR, Lightman S: Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol 2011;22:517-522.
2. Foeldvari I, Wierk A: Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32: 362-365. (Pubitemid 40209138)
3. Dev S, McCallum RM, Jaffe GJ: Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999;106:111-118.
4. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822. (Pubitemid 15104774)
5. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, et al.: Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992;1:142-144.
6. Kempen JH, Daniel E, Gangaputra S, Dreger K, et al.: Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 2008;15:47-55. (Pubitemid 351311499)
7. Gangaputra S, Newcomb CW, Liesegang TL, et al.: Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188e1-2198e1.
8. Thorne JE, et al.: Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112: 1472-1477. (Pubitemid 41074642)
9. Teoh SC, et al.: Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008;146: 752-760, 760e1-e3.
10. Choudhary A, et al.: Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 2006;22: 168-175. (Pubitemid 44051128)
11. Galor A, et al.: Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008;115: 1826-1832.
12. Doycheva D, et al.: Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:1235-1243.
13. Daniel E, et al.: Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-432, e1-e2.
14. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325.
15. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61: 1029-1037.
16. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-232.
17. Langford CA: Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011; 164(suppl 1):31-34.
18. Pujari SS, et al.: Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117: 356-365.
19. Mudun BA, et al.: Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001;9:219-229.
20. O'Duffy JD, Robertson DM, Goldstein NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984; 76:75-84. (Pubitemid 14216363)
21. Zakka FR, et al.: Current trends in the management of ocular symptoms in Adamantiades-Behcet's disease. Clin Ophthalmol 2009;3:567-579.
22. Fang W, Yang P: Vogt-Koyanagi-Harada syndrome. Curr Eye Res 2008;33:517-523. (Pubitemid 351948483)
23. Goldstein DA, et al.: Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002;109:370-377. (Pubitemid 34106047)
24. Kacmaz RO, et al.: Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117:576-584.
25. Masuda K, et al.: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1: 1093-1096. (Pubitemid 19128039)
26. Ben Ezra D, et al.: Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988;20(suppl 4):136-143.
27. Kiss S, et al.: Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005;112:1066-1071. (Pubitemid 40797463)
28. Araujo AA, et al.: Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000;84: 979-982.
29. Vote BJ, et al.: Changing trends in sympathetic ophthalmia. Clin Experiment Ophthalmol 2004;32: 542-545. (Pubitemid 39497033)
30. Malta JB, et al.: Treatment of ocular graft-versushost disease with topical cyclosporine 0.05%. Cornea 2010;29:1392-1396.
31. Roberts CW, Carniglia PE, Brazzo BG: Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 2007;26:805-809. (Pubitemid 47220551)
32. Gumus K, et al.: Topical cyclosporine A as a steroidsparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens 2009;35: 275-278.
33. Utine CA, Stern M, Akpek EK: Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 2010;18:352-361.
34. Hogan AC, et al.: Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:1000-1006.
35. Figueroa MS, Ciancas E, Orte L: Long-term followup of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 2007;17:69-74. (Pubitemid 46580601)
36. Sloper CM, Powell RJ, Dua HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106:723-728. (Pubitemid 30194312)
37. Penninga L, et al.: Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010;66:1177-1187.
38. Reyes J, et al.: Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000;69:2573-2580. (Pubitemid 30482024)
39. Anglade E, Aspeslet LJ, Weiss SL: A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol 2008;2:693-702.
40. Shanmuganathan VA, et al.: The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89:666-669. (Pubitemid 40780569)
41. Phillips BN, Wroblewski KJ: A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect 2011;1:29-34.
42. Tabbara KF, Ai-Hemidan AI: Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008;146:845e1-850e1.
43. Mushtaq B, et al.: Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007;21: 824-825. (Pubitemid 46909189)
44. Taylor SR, et al.: Behcet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011;152:1059-1066.
45. Guignard S, et al.: Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-1634. (Pubitemid 44799677)
46. Rudwaleit M, et al.: Effectiveness, safety, and predictors of good clinical response in 1 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-808.
47. Kim EM, et al.: Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011;38:2218-2223.
48. Lamprecht P: TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev 2005;4:28-34. (Pubitemid 40126369)
49. Jap A, Chee SP: Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008;19: 535-540.
50. Tak PP, Kalden JR: Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 13(suppl 1):S5.
51. Stashenko P, et al.: Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125: 1678-1685. (Pubitemid 10018582)
52. Bar-Or A, et al.: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400. (Pubitemid 351499869)
53. Leandro MJ, et al.: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of patients. Rheumatology (Oxford) 2005;44:1542-1545. (Pubitemid 41742472)
54. Mease PJ, et al.: Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30.
55. Taylor SR, et al.: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-1547.
56. Tappeiner C, et al.: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-186. (Pubitemid 46975985)
57. Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89: 1542. (Pubitemid 41527407)
58. Davatchi F, et al.: Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13:246-252.
59. Sadreddini S, et al.: Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008;18:306-308.
60. de Smet MD, et al.: Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-470.
61. Sobaci G, et al.: Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010;117:1430-1435.
62. Köte I, et al.: The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-335.
63. Onal S, et al.: Long-term efficacy and safety of lowdose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011;129:288-294.
64. Krause L, et al.: Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 2008; 35:896-903. (Pubitemid 351747134)
65. Gueudry J, et al.: Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008;146:837e1-844e1.
66. Sobaci G, Bayraktar Z, Bayer A: Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66. (Pubitemid 41702786)
67. Deuter CM, et al.: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26: 786-791. (Pubitemid 44386101)
68. Bodaghi B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of patients. Br J Ophthalmol 2007;91:335-339. (Pubitemid 46586530)
69. Sen HN, et al.: High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009;148: 696e1-703e1.
70. Wroblewski K, et al.: Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 2011;46:322-328.
71. Onal S, Foster CS, Ahmed AR: Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 2006;14:367-374. (Pubitemid 44949896)
72. Androudi S, et al.: Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005;13:205-212. (Pubitemid 41711292)
73. Kok H, et al.: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916e1-1917e1.
74. Young S, et al.: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2-6. (Pubitemid 32170788)
75. Jonas JB, et al.: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598. (Pubitemid 41108858)
76. Roth DB, et al.: Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009; 116:455-460.
77. Smithen LM, et al.: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743. (Pubitemid 39452920)
78. Haller JA, et al.: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
79. Jaffe GJ, et al.: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirtyfour-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027. (Pubitemid 43795240)
80. Kempen JH, et al.: Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology 2011;118: 1916-1926.
81. Lowder C, et al.: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
82. Taylor SR, et al.: Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116:797-801.
83. Douglas LC, et al.: Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther 2008;31:511-516.
84. Farvardin M, et al.: Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010;30:1530-1535.
85. Theodossiadis PG, et al.: Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 2009; 247:273-281.
86. Giansanti F, et al.: Ocular safety of infliximab in rabbit and cell culture models. J Ocul Pharmacol Ther 2010;26:65-71.
87. Hosseini H, et al.: Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 2009;19:818-823.
88. Pulido JS, et al.: More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 2010; 30:1-5.
89. Weiss K, et al.: Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond) 2009;23: 1812-1818.
90. Mackensen F, et al.: Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008;28: 41-45.
91. Acharya NR, Hong KC, Lee SM: Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148:303e2-309e2.